NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022. The presentation details are as follows:
Protagen Protein Services (PPS) today announced that it will merge with GeneWerk, an Ampersand portfolio company. With the addition of GeneWerk's unique capabilities in vector safety, characterization, and functionality analysis, PPS will complement its current analytical testing offering in protein characterization identity, purity, potency and capsid loading to become a full-service partner in gene therapy testing for the biopharmaceutical industry.